Abstract | OBJECTIVE: To assess the effectiveness and tolerability of ziprasidone for treating pediatric mania. METHODS: This was an eight-week, open-label, prospective study of ziprasidone monotherapy (57.3 +/- 33.9 mg/day) in 21 bipolar youth [manic, mixed, or bipolar not otherwise specified (NOS); 6-17 years old]. Assessments included the Young Mania Rating Scale (YMRS), Clinical Global Impressions-Improvement scale (CGI-I), and Brief Psychiatric Rating Scale (BPRS). Adverse events were assessed through spontaneous self-reports, vital signs, weight monitoring, and laboratory analysis. RESULTS: Fourteen of the 21 youth (67%) completed the study. Ziprasidone treatment was associated with clinically and statistically significant improvement in mean YMRS scores (-10.8 +/- 8.4, p < 0.0001) and 57% had a CGI-I <or=2 at endpoint. Ziprasidone was well tolerated with no statistically significant increase in body weight (0.6 +/- 0.4 kg, p = 0.2) or QTc interval (-3.7 +/- 4.7, p = 0.5). CONCLUSIONS: Open-label ziprasidone treatment was associated with a significant short-term improvement of symptoms of pediatric bipolar disorder. Future placebo-controlled, double-blind studies are warranted.
|
Authors | Joseph Biederman, Eric Mick, Thomas Spencer, Meghan Dougherty, Megan Aleardi, Janet Wozniak |
Journal | Bipolar disorders
(Bipolar Disord)
Vol. 9
Issue 8
Pg. 888-94
(Dec 2007)
ISSN: 1398-5647 [Print] Denmark |
PMID | 18076539
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- Piperazines
- Thiazoles
- ziprasidone
|
Topics |
- Antipsychotic Agents
(therapeutic use)
- Bipolar Disorder
(drug therapy)
- Body Weight
(drug effects)
- Evaluation Studies as Topic
- Female
- Humans
- Male
- Pediatrics
- Piperazines
(therapeutic use)
- Prospective Studies
- Psychiatric Status Rating Scales
- Severity of Illness Index
- Thiazoles
(therapeutic use)
|